Living with Multiple Sclerosis (MS) can be challenging, but advancements in treatment have significantly improved the outlook for many individuals. Among the most impactful developments are B-cell depleting therapies, which target specific immune cells believed to play a crucial role in MS pathology. Two prominent medications in this class are Kesimpta (ofatumumab) and Ocrevus (ocrelizumab). While both are highly effective in managing MS, they differ in several key aspects, including their administration, dosing schedule, and specific indications. Understanding these distinctions is vital for patients and healthcare providers when making informed treatment decisions.
Understanding Multiple Sclerosis (MS)
Before diving into the specifics of Kesimpta and Ocrevus, it's essential to grasp the fundamentals of Multiple Sclerosis. MS is a chronic, often debilitating autoimmune disease that affects the brain, spinal cord, and optic nerves, collectively known as the central nervous system (CNS).
What is MS?
In MS, the body's immune system mistakenly attacks the myelin sheath, a fatty layer that insulates nerve fibers and helps electrical signals travel quickly and efficiently. This attack leads to inflammation and damage to the myelin, a process called demyelination. When myelin is damaged, nerve signals can be slowed, distorted, or completely blocked, leading to a wide range of neurological symptoms. Over time, this damage can also lead to permanent nerve damage and brain atrophy.
Types of MS
- Relapsing-Remitting MS (RRMS): This is the most common form, affecting about 85% of people with MS. It is characterized by clearly defined attacks (relapses) of new or worsening neurological symptoms, followed by periods of partial or complete recovery (remissions). During remissions, symptoms may disappear entirely or remain, but there is no apparent progression of the disease.
- Secondary Progressive MS (SPMS): Many individuals initially diagnosed with RRMS eventually transition to SPMS. In SPMS, the disease course shifts from relapses and remissions to a steady, gradual worsening of neurological function, with or without occasional relapses, minor remissions, or plateaus.
- Primary Progressive MS (PPMS): Affecting about 15% of people with MS, PPMS is characterized by a gradual, continuous worsening of neurological function from the onset, without distinct relapses or remissions.
- Clinically Isolated Syndrome (CIS): This refers to a first episode of neurological symptoms caused by inflammation and demyelination in the CNS that lasts at least 24 hours. While not a definitive MS diagnosis, CIS can be an indicator of a higher risk of developing MS.
Symptoms of MS
MS symptoms are highly variable and depend on which areas of the CNS are affected. They can range from mild to severe and may include:
- Fatigue: Overwhelming tiredness that is not relieved by rest and interferes with daily activities.
- Numbness or Tingling: Often affects the face, body, arms, or legs.
- Vision Problems: Blurred vision, double vision (diplopia), or pain in one eye due to optic neuritis.
- Muscle Weakness and Spasticity: Stiffness and involuntary muscle spasms, making movement difficult.
- Balance and Coordination Issues: Dizziness, vertigo, ataxia (lack of coordination), and difficulty walking.
- Pain: Chronic pain, including neuropathic pain, back pain, or musculoskeletal pain.
- Bladder and Bowel Dysfunction: Frequent urination, urgency, incontinence, or constipation.
- Cognitive Changes: Problems with memory, attention, information processing, and executive functions.
- Emotional Changes: Depression, anxiety, and mood swings.
- Speech Difficulties: Slurred speech (dysarthria).
- Swallowing Problems: Dysphagia.
Causes of MS
The exact cause of MS is unknown, but it is believed to result from a combination of genetic predisposition and environmental factors. It is not contagious or directly inherited. Factors thought to play a role include:
- Genetics: While not directly inherited, having a first-degree relative with MS slightly increases one's risk. Specific genes, particularly those related to the immune system (e.g., HLA-DRB1), are associated with higher risk.
- Environmental Factors:
- Vitamin D Deficiency: Lower levels of vitamin D have been linked to a higher risk of MS.
- Epstein-Barr Virus (EBV): Infection with EBV (which causes mononucleosis) is strongly associated with an increased risk of MS.
- Smoking: Smoking significantly increases the risk of developing MS and is associated with more rapid disease progression.
- Obesity: Childhood and adolescent obesity may increase the risk of MS, particularly in females.
Diagnosis of MS
Diagnosing MS can be challenging as there is no single test. It often involves a combination of clinical evaluation, neurological examination, and diagnostic tests, primarily based on the revised McDonald criteria. The diagnostic process typically includes:
- Neurological Examination: Assessing reflexes, coordination, balance, vision, and other neurological functions.
- Magnetic Resonance Imaging (MRI): MRI of the brain and spinal cord is crucial for detecting lesions (areas of demyelination) characteristic of MS. Gadolinium contrast may be used to identify active inflammation.
- Evoked Potentials: These tests measure electrical activity in the brain in response to sensory stimulation (visual, auditory, or somatosensory) to check for slowed signal transmission.
- Lumbar Puncture (Spinal Tap): Analysis of cerebrospinal fluid (CSF) can reveal oligoclonal bands, which are specific proteins indicative of immune system activity in the CNS, found in about 90% of people with MS.
- Blood Tests: To rule out other conditions that may mimic MS symptoms.
The Role of B-Cell Depleting Therapies in MS Treatment
For many years, MS treatments primarily focused on T-cells, another type of immune cell. However, research has increasingly highlighted the critical role of B-cells in the inflammatory and neurodegenerative processes of MS. B-cells are a type of white blood cell that produce antibodies and present antigens, activating other immune cells. In MS, B-cells contribute to the autoimmune attack by releasing pro-inflammatory cytokines, acting as antigen-presenting cells to T-cells, and potentially forming ectopic lymphoid follicles within the CNS.
B-cell depleting therapies work by targeting and removing B-cells that express the CD20 protein on their surface. By reducing the number of these specific B-cells, these therapies aim to decrease inflammation, reduce the frequency of relapses, and slow the progression of disability in MS.
Kesimpta (Ofatumumab) - A Closer Look
Kesimpta (ofatumumab) is a targeted B-cell depleting therapy approved for the treatment of relapsing forms of MS.
What is Kesimpta?
Kesimpta is a human anti-CD20 monoclonal antibody. It selectively targets CD20-expressing B-cells, leading to their depletion. Unlike some other B-cell therapies, Kesimpta is designed for subcutaneous (under the skin) self-administration.
Mechanism of Action
Ofatumumab binds specifically to the CD20 protein found on the surface of pre-B and mature B-lymphocytes. This binding triggers a cascade of immune responses, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which effectively destroy the targeted B-cells. By depleting these B-cells, Kesimpta reduces the inflammatory activity in the CNS that drives MS relapses and progression. Importantly, hematopoietic stem cells and plasma cells, which do not express CD20, are generally spared, allowing for the eventual regeneration of B-cells and the maintenance of essential immune functions, including immunoglobulin production.
Indications
Kesimpta is approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS).
Administration
One of the distinguishing features of Kesimpta is its route of administration. It is administered as a subcutaneous injection, meaning it is injected under the skin. Patients can learn to self-administer Kesimpta at home using a pre-filled autoinjector pen, after appropriate training from a healthcare professional. This offers significant convenience compared to intravenous infusions.
Dosage and Schedule
The dosing schedule for Kesimpta involves:
- Initial Dosing: 20 mg injected subcutaneously at Weeks 0, 1, and 2.
- Maintenance Dosing: 20 mg injected subcutaneously once every 4 weeks, starting at Week 4.
The initial loading doses help achieve therapeutic B-cell depletion quickly, followed by regular maintenance doses to sustain the effect.
Efficacy
The efficacy of Kesimpta was demonstrated in two pivotal Phase 3 clinical trials, ASCLEPIOS I and ASCLEPIOS II, which compared ofatumumab to teriflunomide (an oral MS medication) in patients with RRMS. Key findings included:
- Reduced Relapse Rate: Ofatumumab significantly reduced the annualized relapse rate (ARR) by over 50% compared to teriflunomide.
- Reduced Disability Progression: Ofatumumab demonstrated a significant reduction in the risk of 3-month confirmed disability progression (CDP) and 6-month CDP.
- Reduced MRI Lesions: Patients treated with ofatumumab had significantly fewer new T1 gadolinium-enhancing lesions and new or enlarging T2 lesions compared to those on teriflunomide.
These results solidified Kesimpta's position as a highly effective disease-modifying therapy for relapsing forms of MS.
Side Effects
Like all medications, Kesimpta can cause side effects. It's important for patients to discuss these with their doctor.
Common Side Effects:
- Injection-site reactions: Redness, swelling, itching, or pain at the injection site. These are usually mild to moderate and tend to decrease over time.
- Upper respiratory tract infections: Such as the common cold or bronchitis.
- Headache.
Serious Side Effects:
- Infections: Kesimpta can increase the risk of serious infections due to its immunosuppressive effects. Patients should be monitored for signs of infection. Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection that has been reported with other anti-CD20 therapies, though not specifically with Kesimpta in clinical trials. However, the risk remains a theoretical concern for any B-cell depleting agent.
- Hepatitis B Virus (HBV) Reactivation: Patients should be screened for HBV before starting treatment.
- Hypogammaglobulinemia: A reduction in immunoglobulin levels, which can increase the risk of infection.
- Malignancies: A theoretical increased risk of certain cancers, though not definitively established in clinical trials for Kesimpta.
Contraindications and Warnings
- Kesimpta is contraindicated in patients with active hepatitis B infection or a history of life-threatening infusion reactions to ofatumumab.
- Patients should be up-to-date on immunizations before starting Kesimpta. Live attenuated vaccines should not be given during treatment and until B-cell repletion occurs.
Special Considerations
- Pregnancy and Breastfeeding: Limited data are available on Kesimpta use in pregnant women. Animal studies suggest potential risks. A pregnancy registry is available. It is not known if ofatumumab is excreted in human milk. Discussion with a healthcare provider is crucial for women who are pregnant, planning to become pregnant, or breastfeeding.
- Vaccinations: Vaccinations with live-attenuated vaccines are not recommended during treatment and until B-cell repletion. Non-live vaccines should be administered at least 4 weeks prior to initiation of Kesimpta.
Ocrevus (Ocrelizumab) - An In-Depth Review
Ocrevus (ocrelizumab) is another highly effective B-cell depleting therapy, notable for being the first and only FDA-approved treatment for primary progressive MS.
What is Ocrevus?
Ocrevus is a humanized anti-CD20 monoclonal antibody. It selectively targets CD20-expressing B-cells, leading to their depletion, similar to Kesimpta. However, Ocrevus is administered via intravenous infusion.
Mechanism of Action
Ocrelizumab binds specifically to the CD20 protein found on the surface of pre-B and mature B-lymphocytes. This binding initiates cell lysis through ADCC and CDC, thereby depleting these B-cells. By reducing the number of pathogenic B-cells, Ocrevus aims to diminish the inflammatory and immune attack on the CNS in MS. Similar to Kesimpta, it spares hematopoietic stem cells and plasma cells, allowing for continued immune function and B-cell regeneration over time.
Indications
Ocrevus is approved by the FDA for the treatment of relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS). Crucially, Ocrevus is also approved for the treatment of primary progressive multiple sclerosis (PPMS) in adults, making it a unique option for this challenging form of the disease.
Administration
Ocrevus is administered as an intravenous (IV) infusion, typically in a clinic or infusion center. Each infusion takes several hours, and patients usually receive premedication (e.g., corticosteroids, antihistamines, antipyretics) to reduce the risk of infusion-related reactions.
Dosage and Schedule
The dosing schedule for Ocrevus involves:
- Initial Dosing: A starting dose of 300 mg is given, followed by a second 300 mg dose two weeks later. This split-dose approach helps to mitigate initial infusion reactions.
- Maintenance Dosing: 600 mg is given as a single infusion every 6 months thereafter.
The bi-annual dosing schedule is a significant convenience for many patients, as it requires only two clinic visits per year.
Efficacy
The efficacy of Ocrevus was established in three key Phase 3 clinical trials:
- For RRMS (OPERA I and OPERA II): These trials compared ocrelizumab to interferon beta-1a. Ocrelizumab significantly reduced the ARR by approximately 47% and 46% respectively, compared to interferon beta-1a. It also significantly reduced the risk of 3-month CDP and the number of new T1 gadolinium-enhancing lesions and new or enlarging T2 lesions.
- For PPMS (ORATORIO): This trial compared ocrelizumab to placebo in patients with PPMS. Ocrelizumab significantly reduced the risk of 3-month CDP by 24% and 6-month CDP by 25% compared to placebo. It also showed a significant reduction in the volume of total brain lesion load and brain volume loss. This trial was groundbreaking as it demonstrated the first effective treatment for PPMS.
Side Effects
Patients should be aware of potential side effects and discuss any concerns with their healthcare provider.
Common Side Effects:
- Infusion-related reactions: These can occur during or within 24 hours of an infusion and may include itching, rash, hives, redness, flushing, low blood pressure, fever, fatigue, dizziness, headache, throat irritation, shortness of breath, or nausea. Premedication helps manage these.
- Upper respiratory tract infections.
- Skin infections.
Serious Side Effects:
- Infections: Increased risk of serious infections, including upper respiratory tract infections, skin infections, and potentially more severe opportunistic infections. Regular monitoring for signs of infection is crucial.
- Progressive Multifocal Leukoencephalopathy (PML): A rare but severe brain infection. While no cases of PML have been directly attributed to Ocrevus in clinical trials, the risk is associated with B-cell depleting therapies.
- Hepatitis B Virus (HBV) Reactivation: Patients should be screened for HBV before starting treatment.
- Hypogammaglobulinemia: Decreased immunoglobulin levels, which can increase the risk of infection.
- Malignancies: There has been an observed imbalance in the number of breast cancer cases in Ocrevus-treated patients compared to placebo or interferon beta-1a in clinical trials. This risk is still being investigated, and patients should undergo routine cancer screening as recommended for their age and risk factors.
Contraindications and Warnings
- Ocrevus is contraindicated in patients with active hepatitis B infection or a history of life-threatening infusion reactions to ocrelizumab.
- Patients should be up-to-date on immunizations before starting Ocrevus. Live attenuated vaccines should not be given during treatment and until B-cell repletion occurs.
Special Considerations
- Pregnancy and Breastfeeding: A pregnancy exposure registry is available for Ocrevus. Limited data exist, and animal studies suggest potential for B-cell depletion in newborns. It is not known if ocrelizumab is excreted in human milk. Women who are pregnant, planning to become pregnant, or breastfeeding should have a thorough discussion with their neurologist about the risks and benefits.
- Vaccinations: Vaccinations with live-attenuated vaccines are not recommended during treatment and until B-cell repletion. Non-live vaccines should be administered at least 4 weeks prior to initiation of Ocrevus.
Direct Comparison: Kesimpta vs. Ocrevus
While both Kesimpta and Ocrevus are highly effective anti-CD20 monoclonal antibodies used to treat MS, their differences often influence treatment choice.
Key Similarities
- Mechanism of Action: Both drugs selectively target and deplete CD20-expressing B-cells, reducing inflammatory activity in the CNS.
- High Efficacy: Both have demonstrated superior efficacy in reducing relapse rates and slowing disability progression compared to older MS therapies in clinical trials.
- Safety Profile: Both share similar serious risks, including increased susceptibility to infections (e.g., upper respiratory, skin, urinary tract infections), potential for HBV reactivation, and a theoretical risk of PML. Both can lead to hypogammaglobulinemia.
- Monitoring Requirements: Patients on either medication require regular monitoring for infections, immunoglobulin levels, and general health.
Key Differences
- Administration Route:
- Kesimpta: Subcutaneous injection. Patients can self-administer at home.
- Ocrevus: Intravenous infusion. Requires visits to a clinic or infusion center.
- Dosing Frequency:
- Kesimpta: Monthly injections (after initial loading doses).
- Ocrevus: Bi-annual infusions (every six months), after an initial split dose.
- Indications:
- Kesimpta: Approved for relapsing forms of MS (CIS, RRMS, active SPMS).
- Ocrevus: Approved for relapsing forms of MS (CIS, RRMS, active SPMS) AND primary progressive MS (PPMS). This is a crucial distinction for patients with PPMS.
- Reaction Profiles:
- Kesimpta: More common to experience injection-site reactions (redness, swelling, pain).
- Ocrevus: More common to experience infusion-related reactions (e.g., itching, rash, headache, fever, flushing) which are managed with premedication.
- Patient Convenience and Lifestyle Impact:
- Kesimpta: Offers the convenience of home administration, which can be appealing for those who prefer not to visit a clinic frequently or have difficulty with travel.
- Ocrevus: Requires fewer total dosing days per year (two infusions), which can be convenient for those who prefer not to manage monthly injections or who are comfortable with clinic visits. The longer interval between doses may also be appealing.
- Cost and Access: Both medications are high-cost specialty drugs. Insurance coverage, patient assistance programs, and prior authorization requirements are significant considerations for both.
Choosing Between Kesimpta and Ocrevus: What to Consider
The decision between Kesimpta and Ocrevus is a highly personalized one that should be made in close consultation with a neurologist. Several factors will influence this choice:
- Type of MS: If a patient has PPMS, Ocrevus is currently the only FDA-approved B-cell depleting option. For relapsing forms of MS, both are viable.
- Patient Preference for Administration: Do you prefer monthly self-injections at home or bi-annual infusions at a clinic? Consider factors like fear of needles, comfort with self-administration, and the time commitment for clinic visits.
- Tolerance for Side Effects: While both have similar serious risks, the common side effects differ (injection-site reactions vs. infusion reactions). Your doctor can help you understand which profile might be better suited for you.
- Comorbidities and Health Status: Any existing medical conditions or medications could influence the choice, particularly regarding infection risk or other drug interactions.
- Lifestyle and Travel: The flexibility of home administration versus scheduling clinic visits can impact travel plans or daily routines.
- Insurance Coverage and Financial Considerations: The out-of-pocket costs, deductibles, and co-pays can vary significantly between medications and insurance plans.
- Physician Experience: Your neurologist's experience and comfort level with either drug may also play a role.
Ultimately, the goal is to find a treatment that is not only effective in controlling MS disease activity but also fits into your lifestyle and minimizes adverse effects, ensuring long-term adherence and improved quality of life.
Prevention of MS
Currently, there is no definitive way to prevent MS, as its exact cause remains unknown. However, research suggests several factors that may reduce the risk of developing MS or influence its progression:
- Vitamin D Supplementation: Maintaining adequate vitamin D levels, especially through sun exposure and supplements, has been associated with a lower risk of MS.
- Smoking Cessation: Quitting smoking is strongly recommended, as it is a known risk factor for developing MS and for more rapid disease progression.
- Managing Epstein-Barr Virus (EBV) Exposure: While direct prevention of EBV infection is difficult, ongoing research explores the link between EBV and MS, potentially leading to future preventive strategies like vaccines.
- Healthy Lifestyle: A balanced diet, regular exercise, and maintaining a healthy weight contribute to overall immune health and may indirectly influence MS risk.
When to See a Doctor
It is crucial for individuals with MS, or those experiencing potential MS symptoms, to maintain regular communication with their healthcare team:
- For new or worsening MS symptoms: Any new neurological symptoms, or a significant worsening of existing ones, warrant immediate medical attention. This could indicate a relapse or disease progression.
- To discuss treatment options: If you are newly diagnosed, considering a change in treatment, or want to explore advanced therapies like Kesimpta or Ocrevus, schedule an appointment with your neurologist.
- Experiencing severe side effects: If you develop any severe or concerning side effects from your current MS medication, contact your doctor right away.
- For routine follow-ups: Regular appointments with your neurologist are essential to monitor disease activity, assess treatment effectiveness, manage symptoms, and adjust your treatment plan as needed.
- Before making lifestyle changes: Always consult your doctor before starting new diets, exercise routines, or supplements, especially when managing a chronic condition like MS.
FAQs About Kesimpta and Ocrevus
Are Kesimpta and Ocrevus equally effective?
Both Kesimpta and Ocrevus are highly effective B-cell depleting therapies for relapsing forms of MS. Direct head-to-head trials comparing the two are not available, but indirect comparisons and clinical trial data suggest comparable efficacy in reducing relapse rates and slowing disability progression in RRMS. Ocrevus has the unique distinction of being approved for PPMS.
Which one is safer?
Both drugs share similar serious safety concerns, primarily related to increased infection risk and theoretical risks of PML and malignancies. The common side effect profiles differ (injection-site reactions for Kesimpta vs. infusion reactions for Ocrevus). The choice often comes down to individual patient risk factors, preferences, and the specific MS type.
Can I switch from Ocrevus to Kesimpta, or vice versa?
Switching between B-cell depleting therapies is possible and may be considered by your neurologist based on factors like side effect tolerance, convenience, or disease activity. The timing of the switch and any washout periods would be carefully managed by your healthcare provider to ensure continuous disease control and minimize risks.
Do these drugs cure MS?
No, neither Kesimpta nor Ocrevus are cures for MS. They are disease-modifying therapies (DMTs) that work by reducing the frequency and severity of relapses, slowing the accumulation of disability, and reducing new lesion formation in the brain and spinal cord. They aim to manage the disease and improve long-term outcomes.
What about pregnancy while on these medications?
Limited data are available on the use of Kesimpta and Ocrevus during pregnancy. Both drugs can deplete B-cells in the fetus. Women who are pregnant or planning to become pregnant should have an in-depth discussion with their neurologist to weigh the risks and benefits and consider available pregnancy registries. Contraception is generally recommended during treatment and for a period after the last dose.
How long do I need to take these drugs?
MS is a chronic condition, and disease-modifying therapies like Kesimpta and Ocrevus are typically taken long-term to continuously manage disease activity. Treatment duration is determined by ongoing efficacy, tolerability, and shared decision-making between the patient and their neurologist.
Are there other B-cell depleting therapies for MS?
Yes, other B-cell depleting therapies are available or in development. Rituximab (Rituxan), an older anti-CD20 antibody, is used off-label for MS in some regions. Other emerging therapies may also target B-cells or other immune pathways. Your neurologist can discuss the full spectrum of available treatments.
Sources / Medical References
- U.S. Food and Drug Administration (FDA) prescribing information for Kesimpta (ofatumumab) and Ocrevus (ocrelizumab).
- Clinical trial data: ASCLEPIOS I & II (Kesimpta), OPERA I & II (Ocrevus for RRMS), ORATORIO (Ocrevus for PPMS).
- National Multiple Sclerosis Society (NMSS) guidelines and educational materials.
- Peer-reviewed medical journals and publications on Multiple Sclerosis and B-cell depleting therapies.
- Healthcare provider's clinical experience and expert consensus.
Conclusion
Kesimpta and Ocrevus represent significant advancements in the treatment of Multiple Sclerosis, offering powerful B-cell depletion to effectively manage disease activity. While sharing a common mechanism of action and high efficacy for relapsing forms of MS, their differences in administration, dosing frequency, and specific indications (especially Ocrevus's approval for PPMS) provide distinct options for patients.
The choice between Kesimpta and Ocrevus is a highly individual one, requiring a thorough discussion with your neurologist. Factors such as your specific type of MS, personal preferences for treatment administration, lifestyle, and potential side effects will all play a crucial role in determining the most suitable therapy for you. With ongoing research and these innovative treatments, individuals with MS have more tools than ever to manage their condition and maintain a better quality of life.
